(Q36114473)

12 August 2017

1 reference

title

Regulatory T cells and tumor immunity (English)

1 reference

12 August 2017

author name string

Subhasis Chattopadhyay

series ordinal

1

1 reference

12 August 2017

Nitya G Chakraborty

series ordinal

2

1 reference

12 August 2017

Bijay Mukherji

series ordinal

3

1 reference

12 August 2017

language of work or name

1 reference

3 May 2005

1 reference

Cancer Immunology, Immunotherapy

12 August 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

12 August 2017

volume

54

1 reference

12 August 2017

issue

12

1 reference

12 August 2017

page(s)

1153-1161

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-005-0699-9

12 August 2017

exact match

0 references

cites work

CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-005-0699-9

Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-005-0699-9

Inhibition of human CD4(+)CD25(+high) regulatory T cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-005-0699-9

Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-005-0699-9

Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-005-0699-9

Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-005-0699-9

10.1007/S00262-005-0699-9

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference